Ellicott City, MD, United States of America

Boro Dropulic

This inventor holds 50 USPTO granted patents and 20 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Lentigen Technology, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, Johns Hopkins University. Active years: 1999-2026.

USPTO Granted Patents = 50 (Patent Applications = 20)

% Patents Active = 92.0

CIPO Patents = 4 (Patent Applications = 21)

EPO Patents = 13 (Patent Applications = 29)

Average Co-Inventor Count = 3.5

ph-index = 5

Forward Citations = 123(Granted Patents)

Location History:

Ellicott, MD (US) (2019)
Ellicott City, MD (US) (1999 - 2024)
Gaithersburg, MD (US) (2019 - 2024)

Company Filing History:

38 out of 40

Lentigen Technology, Inc.

patents

15 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7 out of 3,795

Johns Hopkins University

University of Colorado

patents

where one patent can have more than one assignee

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

DuoCARs

Engineered T-Cells

Anti-ROR1

Anti-CD38

Anti-BCMA

Anti-CD19

Chimeric Antigen Receptors

Anti-CD22

Anti-CD33

Anti-mesothelin

HIV Immunotherapy

Nucleic Acid Expression

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12714750 - Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy (2026-08-25),

2. 12624104 - Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy (2026-05-12),

3. 12540179 - Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy (2026-02-03),

4. 12391958 - Compositions and methods for treating cancer with anti-CD38 immunotherapy (2025-08-19),

5. 12391740 - Compositions and methods for treating cancer with anti-BCMA immunotherapy (2025-08-19),

6. 12371490 - Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy (2025-07-29),

7. 12365718 - Compositions and methods for treating cancer with DuoCARs (2025-07-22),

8. 12193995 - Method to treat cancer with engineered T-cells (2025-01-14),

9. 12122831 - Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy (2024-10-22),

10. 12037403 - Compositions and methods for treating cancer with anti-CD123 immunotherapy (2024-07-16),

11. 12024554 - Compositions and methods for treating HIV/AIDS with immunotherapy (2024-07-02),

12. 11970528 - Compositions and methods for treating cancer with anti-mesothelin immunotherapy (2024-04-30),

13. 11969443 - Compositions and methods for treating cancer with self-driving chimeric antigen receptors (2024-04-30),

14. 11905515 - Chimeric antigen receptors and methods of use (2024-02-20),

15. 11878052 - Compositions and methods for treating cancer with anti-CD22 immunotherapy (2024-01-23),

Title: Inventor Spotlight: Boro Dropulic Revolutionizing Cancer Treatment

Introduction:

Boro Dropulic, a distinguished inventor based in Ellicott City, MD, has made significant contributions to the field of oncology with his groundbreaking patents and innovative research in cancer treatment.

Latest Patents:

Dropulic's latest patents showcase his cutting-edge approach to treating cancer. His inventions focus on utilizing chimeric antigen receptors to effectively target cancer cells. The patents detail novel compositions and methods for leveraging anti-mesothelin immunotherapy and self-driving chimeric antigen receptors in the fight against cancer.

Career Highlights:

With an impressive portfolio of 39 patents, Dropulic has demonstrated a deep commitment to advancing cancer therapies. Throughout his career, he has collaborated with renowned institutions and companies to translate his innovative ideas into tangible solutions for patients in need.

Collaborations:

Dropulic's collaborative spirit is evident through his work with esteemed colleagues such as Dina Schneider and Rimas J. Orentas. Together, they have spearheaded research initiatives that have the potential to reshape the landscape of cancer treatment.

Conclusion:

In conclusion, Boro Dropulic stands as a pioneering figure in the field of oncology, with a passion for innovation and a relentless drive to make a difference in the lives of those affected by cancer. His patents and collaborations underscore his commitment to pushing the boundaries of medical science and revolutionizing the way we approach cancer treatment.